Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2020 - 12 - 15 save search
UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2020-12-15 (Crawled : 17:02) - globenewswire.com
RFL 4 | $1.74 0.0% 8.5K
|
Finance
|
| O: 2.24%
H: 8.21%
C: -7.01%
fda leukemia treatment fast track fda fast track cpi-613 myeloid leukemia fast track designation designation acute myeloid leukemia aml
FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19
Published: 2020-12-15 (Crawled : 16:00) - biospace.com/
HUGE | News | $0.469 -4.09% -4.26% 110K
|
Process Industries
|
| O: 2.73%
H: 1.06%
C: -5.85%
covid trial treatment phase 2
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
Published: 2020-12-15 (Crawled : 14:02) - globenewswire.com
ABIO | $3.67 6.38% 5.99% 210K
|
Health Technology
|
| O: -0.93%
H: 1.88%
C: -2.58%
biopharma covid trial treatment potential phase 2b covid-19 enroll
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2020-12-15 (Crawled : 14:02) - globenewswire.com
RFL 4 | $1.74 0.0% 8.5K
|
Finance
|
| O: 2.24%
H: 8.21%
C: -7.01%
fda leukemia treatment fast track fda fast track cpi-613 myeloid leukemia fast track designation designation acute myeloid leukemia aml
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Published: 2020-12-15 (Crawled : 14:01) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 3.14%
H: 1.5%
C: -2.26%
phase 3 treatment enroll
Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
Published: 2020-12-15 (Crawled : 13:05) - globenewswire.com
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 3.84%
H: 0.25%
C: -1.9%
disease biotech therapy treatment breakthrough therapy designation
Enzo Biochem Hosting Key Opinion Leader Call on GENFLEX™ Molecular System for COVID-19 and the Role of Testing in a Post-Vaccine Treatment Environment
Published: 2020-12-15 (Crawled : 13:02) - globenewswire.com
ENZ | $1.09 0.0% 76K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: -2.76%
covid test molecular vaccine treatment
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
Published: 2020-12-15 (Crawled : 12:02) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 3.34%
H: 1.57%
C: -9.06%
fda approval fda approval actinic keratosis treatment tirbanibulin
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2020-10-09 (Crawled : 10:21) - investor.alkermes.com
ALKS | $24.26 0.79% 0.78% 1.2M
|
Health Technology
| Email alert
Add to watchlist
fda schizophrenia treatment
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
Published: 2018-09-13 (Crawled : 10:16) - globenewswire.com
VTGN | $4.83 1.05% 1.04% 190K
|
Health Technology
| Email alert
Add to watchlist
drug license phase 3 treatment social anxiety disorder
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
Published: 2018-10-03 (Crawled : 10:16) - globenewswire.com
VTGN | $4.83 1.05% 1.04% 190K
|
Health Technology
| Email alert
Add to watchlist
fda opioid treatment fast track fda fast track fast track designation designation
VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
Published: 2018-11-12 (Crawled : 10:16) - globenewswire.com
VTGN | $4.83 1.05% 1.04% 190K
|
Health Technology
| Email alert
Add to watchlist
depression patent treatment
VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
Published: 2019-02-13 (Crawled : 10:16) - globenewswire.com
VTGN | $4.83 1.05% 1.04% 190K
|
Health Technology
| Email alert
Add to watchlist
depression patent treatment
VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
Published: 2019-02-19 (Crawled : 10:16) - globenewswire.com
VTGN | $4.83 1.05% 1.04% 190K
|
Health Technology
| Email alert
Add to watchlist
depression patent treatment
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.